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ABSTRACT
Microwave induced synthesis has various advantages over conventional synthesis, such as
highly accelerated reaction rate , reasonable better yields, simple opensyst ms, no solvent
or very less amount of solvents required, eco friendly method, clean heating system and
control on reaction parameters .In the present work novel Schiff’s bases containing
thiadiazole scaffold and benzamide group, through appropriate pharmacophore were
designed and synthesized , because of the important biological properties associated with
thesethreemoieties/groups. Thecouplingof theseimportantmoietieswasachievedunder
microwave irradiation. A facile, solvent-free synthesis of a series of N-((5-(substituted
methylene amino)-1,3,4-thiadiazol-2-yl)methyl)benzamide was carried outunder
microwave-irradiation. Solvent free synthesis of novel Schiff bases was achieved by cyclo
addition of various aromatic aldehydes (0.01 mol) and N-((5-amino-1,3,4-thiadiazol-2
yl)methyl)benzamide(0.01 mol)in presence of catalytic amount of glacial acetic acid
Under microwave irradiation. The same compounds were also synthesized using
conventional approach. The conventional method required 15-18 hrs, while microwave
irradiation method required only 15-20 minutes and gave better yields.
2
Total 12 final compounds were synthesized as per the scheme reported. Structures of
synthesized compounds were confirmed by IR, NMR, and Mass spectral study.All the
designed hybrids were evaluated for theirin vitro anticancer activity against a panel of four
human cancer cell lines viz SK-MEL-2(melanoma), HL-60 (leukemia), HeLa (cervical) and
MCF-7 using MTT assays method. Most of the synthesized compounds exhibited
promising anticancer activity with the some compounds having GI50 values similar to that
of theAdriamycin. Thecompounds7k, 7l, 7b, and7a werefoundto bethemostpromising
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in this study. A computational study of synthesized compounds7(a–l) was performed for
prediction of ADMET. The absorption, distribution, metabolism, excretion andToxicity
(ADMET) properties of all compounds were predicted using Qikprop v3.5 (Schrödinger
LLC).
Keywords: Micro-wave assisted synthesis, Schiff's bases, thiadiazoles, MTTassay,in-vitro
anti-cancer activity
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths
(around 13% of all deaths) in 2008h.
Cancer is a generic term for a large group of diseases that can affect anypart of the
body. Other terms used are malignant tumours and neoplasms.
One defining feature of cancer is the rapid creation of abnormal cells that grow beyond
their usual boundaries, and which can then invade adjoining parts of the body and





• Review of literature shows that 1,3,4-Thiadiazole has gained prominence by
exhibiting a wide variety of biological activities. It has interesting
pharmacophores that display a broad spectrum biological activity. The lower
toxicity and in vivo stability of 1,3,4-thiadiazole nucleus are attributed to its
aromaticity. Diverse chemical structures containing1,3,4-Thiadiazole nucleus
have been reported with potential anticancer activity.The1,3,4-thiadiazole ring
in anticancer agents performs its role in pharmacophroes ofap ptosis inducers
and caspase activators, tyrosine kinase inhibitors, carbonic anhydrase inhibitors
and etc. Hence, various mechanisms could beimagined for anticancer chemical
structures that containing the 1,3,4-thiadiazole ring.
• In review of literaturethe Schiff basederivativeshavebeenfound to be more
potent molecules ininhibiting cancer cell lines. This is due to the presence of
carbon–nitrogen double bond having potential receptor binding ability. Schiff
bases are also one of the intensively investigated classes of aromatic and
heteroaromatic compounds. This class of compounds showed avariety of
applications ranging from anticancer, antibacterial, diuretic (Supran et al.,
1996),antifungal and anti parasitic activity. They have also medicinal importance
and are used in drug design due to their activity against a wide range of
organisms. This importance of thiadiazole nucleus and Schiff’s bases and
continuing demand for new anticancer agents, prompted us toynthesize
different Schiff base derivatives of 1, 3, 4-thiadiazole ring. 5
Microwave Induced Green Synthesis
In the present work microwave-assisted synthetic protocol is reported.
Microwave is an important tool in Green synthesis. Microwave reactions involve 
selective absorption of electromagnetic waves by polar molecules, non-polar 
molecules being inert to microwave. Microwave induced organic reaction 
enhanced more. Green synthesis is a simplest method for conducting microwave 
assisted reactions which involves irradiation of reactants in an open vessel at fixed 
frequency of 2.45GHz. This method was developed by Bose et al.
Advantages of microwave induced synthesis:
Microwave induced synthesis has various advantages ov r conventional synthesis. 
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These are as follows:
Highly accelerated reaction rate 
Reasonable good yields 
Simple open systems 
No solvent or very less amount of solvents required 
Eco friendly method 
Clean heating system 
Control on reaction parameters
Mechanism Of Action Of Anticancer Drugs
 Block nucleic acid (DNA, RNA) biosynthesis
 Directly destroy DNA and inhibit DNA reproduction
 Interfere transcription and block RNA synthesis
 Interfere protein synthesis and function
 Influence hormone homeostasis
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Need For Study
Discovery of new anticancer agents is the need of the hour due to:
1. Development of resistance by cancer cells.
2. Abnormal nature of cancer cells.
3. High toxicity and side effects by anticancer agents.
4. High rate of mortality due to cancer. 
5. Changes in lifestyle. With the recent advent in technology, it is possible to 
harness the presently available molecules for different pharmacological 
actions.
6. Anticancer drugs are one such class of drugs which st ll has a lot of scope 
for modulation and discovery. 
7. Many heterocyclic compounds show multiple pharmacological activities 
including the anticancer activity.
8. Keeping the current medical needs in mind, the het rocyclic thiadiazole
derivatives can be targeted for study.
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Objective
 To design and synthesize Schiff base derivatives of heterocyclic 1,3,4
thiadiazole scaffold.
 To conduct physicochemical characterization of intermediates and synthesized
compounds.
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 To confirm the structures of synthesized compounds by chemical tests, and
spectral techniques such as FT-IR, ES-MS and NMR.
 In-vitro anticancer screening of the synthesized compound on human cancer
cell lines viz. HL-60(leukemia), MCF-7 (breast), HeLa (cervical) and SK-
MEL-2 (melanoma)
Scheme of  Synthesis
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EXPERIMENTAL
Step I: General process for synthesis of 2-Benzamidoacetica id
0.33mol of glycine (2) was dissolved in 250ml of 10% NaOH soluti n contained
in a conical flask.0.385mol of benzoyl chloride (1) was added in 5-portion to the
solution and shaken vigorously until all the chloride has react d. The solution
was transferred to a beaker containing crushed ice and dil. HCl was added until
the solution was acidic to congored paper. The resulting crystalline solid was
collected and boiled with 10 ml of CCl4 for 10 min. The product was filtered and
washedwith CCl . Thesolidproductobtainedwasdriedandrecrystallizedfrom4
ethanol. The melting point and yield were recorded.
Step II: General procedure for synthesis of N-((5-amino-1,3,4-thiadiazol-2-
yl)methyl) benzamide
2- Benzamidoacetic acid (3) (0.05mol) was refluxed with thiosemicarbazide (4)
(0.05mol) and phosphorus oxychloride (15 ml) for 1hr. The mixture was cooled
and diluted with water (90 ml) and again refluxed for 4 hrs. Then the mixture
was filtered and filtrate was basified with potassium hydroxide solution. The
precipitate was filtered off and recrystallized from ethanol.
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Microwave-assisted method
Solvent free synthesis of Schiff bases was achieved by cycloaddtion of various
aromatic aldehydes (0.01 mol) and N-((5-amino-1,3,4-thiadiazol-2-
yl)methyl)benzamide (0.01 mol)in presence of catalytic amount of glacial acetic
acid under microwave irradiation. The synthesized products were recrystallized
from ethanol. The same compounds were also synthesized using co ventional
approach. A comparativestudy in terms of yield and reactionperiod has been
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reported using conventional method. The reaction carried out using conventional
method required about 15-18 hrs, while microwave irradiation method required
only 15-20 min. The yield was about 95% using microwave method while
conventional method yield was around 35%.









7a C17H13ClN4OS 356.83 95 124-128 0.44
7b C17H12Cl2N4OS 391.27 92 112-114 0.56
7c C17H14N4O2S 338.38 94 112-114 0.59
7d C17H14N4O2S 338.38 94 106-108 0.43
7e C18H16N4O3S 368.41 92 122-126 0.66
OH
Table 1Physical characterization of the synthesized compounds7 (a-l)
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Solvent system chosen for Rf value determination was Chloroform: methanol (8:2).
7f C19H18N4O3S 382.44 92 130-132 0.45
7g C18H16N4O2S 352.41 95 112-118 0.57
7h C19H18N4O3S 382.44 88 114-118 0.64
7i C20H20N4O4S 412.26 86 138-140 0.48
7j C20H20N4O4S 412.26 88 134-138 0.70
7k C15H12N4O2S 312.35 85 124-126 0.55
7l C15H12N4OS2 328.41 84 136-138 0.42
Spectral characterization
Synthesized compounds were confirmed by FTIR,1HNMR,13C
NMR and Mass spectroscopic studies.
All the spectral data were in accordance with assumed structures IR
spectra were scanned on JASCO made FTIR-PS 4000, within 4000-
400 cm-1 wavelengthrange. KBr powdertechniquewas usedfor the
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sampling purpose.
The 1H NMR and 13C NMR spectra of synthesized compounds were
recorded on BrukerAvance II 400 NMR Spectrometer at 400 MHz
Frequency in deuterated DMSO and CDCl3 and using TMS as internal
standard (chemical shiftδ in ppm. Mass spectra of some compounds
were scanned on Water’s Micromass Q-Tof system. The spectral dat are
in accordance with assumed structures.
Spectral study
(E)-N-((5-(4-chlorobenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl)benzamide (7a)
Yield: 95%; M.P: 126-1280C ; IR (KBrvmax in cm
-1): 3350.41 (NH), 2970.76 (C=H), 1810.26
(C=O of amide);1H NMR (DMSO) δ ppm: 3.42 (s, 2H, CH2), 6.69-5.2 (m, 9H), 8.21 (s, 1H,
NH), 10.33 (s, 1H, N=CH);13C NMR (DMSO) δ ppm: 168.00, 167.89, 160.00, 136.67,
134.51, 134.34, 133.23, 131.22, 130.63, 130.00, 128.98, 128.78, 127.51, 127.34, 127.36,
39.11; m/z: 356.05 (100.0%), 358.05 (37.1%), 357.05 (20.7%), 359.05 (7.1%), 358.06
(1.6%), 360.04 (1.5%); Molecular Formula: C17H13ClN4OS Elemental Analysis: Calculated:




Yield: 92%; M.P: 112-1140C ; IR (KBrvmax in cm
-1): 3352.41 (NH), 2975.76 (C=H), 1818.26
(C=O of amide);1H NMR (DMSO) δ ppm: 3.45 (s, 2H, CH2), 6.69-5.2 (m, 8H), 8.29 (s, 1H,
NH), 10.33 (s, 1H, N=CH);13C NMR (DMSO) δ ppm: 169.00, 168.89, 161.00, 136.77,
134.41, 134.39, 133.13, 131.22, 130.53, 130.00, 128.98, 128.68, 127.51, 127.34, 127.36,
40.11; m/z: 390.01 (100.0%), 392.01 (68.9%), 391.01 (20.7%), 393.01 (13.2%), 394.00
(13.1%), 395.01 (2.5%), 392.02 (1.8%), 394.01 (1.5%), 393.00 (1.0%); Molecular Formula:
C17H12Cl2N4OS; Elemental Analysis: Calculated: (C, H, Cl, N, O, S) 52.18, 3.09, 18.12,
14.32, 4.09, 8.20, Found: 52.17, 3.07, 18.14, 14.30, 4.08, 8.22.
(E)-N-((5-(4-hydroxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl)benzamide (7c)
Yield: 94%; M.P: 112-1140C ; IR (KBrvmax in cm
-1): 3350.41 (NH), 3179.92 (OH), 2970.76
(C=H), 1810.26 (C=O of amide);1H NMR (DMSO) δ ppm: 3.44 (s, 2H, CH2), 5.43 (s,1H,
OH), 6.69-5.2 (m, 9H), 8.21 (s, 1H, NH), 10.34 (s, 1H, N=CH);13C NMR (DMSO)δ ppm:
190.00, 168.54, 165.05, 163.36, 156.36, 134.60, 131.90,129.41, 128.96, 125.20, 121.93,
116.19, 115.80, 40.12; m/z: 338.08 (100.0%), 339.09 (18.6%), 340.08 (4.8%), 339.08
(2.3%), 340.09 (2.2%); Molecular Formula: C17H14N4O2S Elemental Analysis: Calculated:
(C, H, N, O, S) 60.34, 4.17, 16.56, 9.46, 9.48, Found: 60.30, 4.18, 16.59, 9.43, 9.45.
(E)-N-((5-(2-hydroxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl)benzamide (7d)
Yield: 94%; M.P: 106-1080C ; IR (KBrvmaxin cm
-1): 3350.58 (NH), 3179.90 (OH), 2970.66
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(C=H), 1811.16 (C=O of amide);1H NMR (DMSO) δ ppm: 4.12 (s, 2H, CH2), 5.38 (s, 1H,
OH), 7.02-7.71 (m, 4H), 7.81-8.10 (m, 5H), 8.16 (s, 1H, NH), 9.91(s, 1H, N=CH);13C NMR
(DMSO) δ ppm: 170.11, 169.09, 160.99, 160.55, 135.51, 132.41, 131.00, 129.80, 128.17,
127.91, 127.45, 126.89, 121.46, 120.52, 118.82, 40.03; m/z: 338.08 (100.0%), 339.09
(18.6%), 340.08 (4.8%), 339.08 (2.3%), 340.09 (2.2%); Molecular Formula: C17H14N4O2S;
Elemental Analysis: Calculated: (C, H, N, O, S) 60.34, 4.17, 16.56, 9.46, 9.48Found:
60.30, 4.19, 16.58, 9.49, 9.50.
(E)-N-((5-(4-hydroxy-3-methoxybenzylideneamino)-1,3,4-thiadiazol-2-
yl)methyl)benzamide (7e)
Yield: 92%; M.P: 122-1260C ; IR (KBrvmax in cm
-1): 3350.31 (NH), 2971.76 (C=H), 1810.16
(C=O of amide);1H NMR (DMSO) δ ppm: 3.83 (s, 3H, OCH3), 4.10 (s, 2H, CH2), 5.35 (s,
1H, OH), 6.93 (d, 1H), 7.34 (d, 1H), 7.52 (s, 1H), 7.70-8.08 (m, 5H), 8.19 (s, 1H, NH),
10.00 (s, 1H, N=CH);13C NMR (DMSO) δ ppm: 169.18, 167.71, 159.99, 152.09, 149.71,
135.09, 130.16, 129.98, 128.28, 127.76, 127.01, 126.81, 122.15, 118.16, 113.17, 56.17,
39.87; m/z: 368.09 (100.0%), 369.10 (19.8%), 370.09 (4.8%), 370.10 (2.6%), 369.09
(2.3%); Molecular Formula: C18H16N4O3S; Elemental Analysis: Calculated: (C, H, N, O, S)




Yield: 92%; M.P: 130-1320C; IR (KBrvmax in cm
-1): 3350.31 (NH), 2971.76 (C=H), 1810.16
(C=O of amide);1H NMR (DMSO) δ ppm: 1.32 (t, 3H, CH3), 4.09 (q, 2H, CH2), 4.46 (s,
2H, CH2), 5.35 (s, 1H, OH), 6.91-7.52 (m, 3H, CH), 7.63-8.09 (m, 5H, CH), 8.13 (s, 1H,
NH), 10.00 (s, 1H, N=CH);13C NMR (DMSO) δ ppm: 168.78, 161.66, 151.88, 148.83,
134.47, 132.55, 130.70, 128.88, 128.19, 127.00, 122.34, 116.59, 112.38, 64.57, 39.99,
14.87; m/z: 382.11 (100.0%), 383.11 (22.9%), 384.11 (5.6%), 384.12 (2.1%); Molecular
Formula: C19H18N4O3S; Elemental Analysis: Calculated: (C, H, N, O, S) 59.67, 4.74, 14.65,
12.55, 8.38, Found: 59.64, 4.72, 14.61, 12.57, 8.39.
(E)-N-((5-(4-methoxybenzylideneamino)-1,3,4-thiadiazol-2-yl)methyl)benzamide (7g)
Yield: 95%; M.P: 114-1180C ; IR (KBrvmax in cm
-1): 3352.18 (NH), 2971.66 (C=H), 1810.17
(C=O of amide);1H NMR (DMSO) δ ppm: 3.83 (s, 6H, OCH3), 4.19 (s, 2H, CH2), 7.06 (d,
1H), 7.16 (d, 1H), 7.60-8.06 (m, 7H), 8.17 (s, 1H, NH), 10.00 (s, 1H, N=CH);13C NMR
(DMSO) δ ppm: 170.13, 169.99, 163.09, 161.00, 135.01, 132.96, 131.91, 130.71, 128.89,
128.01, 127.97, 127.52, 127.03, 114.45, 114.01, 55.89, 40.00; m/z: 352.10 (100.0%), 353.10
(21.8%), 354.10 (5.4%), 354.11 (1.8%); Molecular Formula: C18H16N4O2S; Elemental





Yield: 88%; M.P: 114-1160C ; IR (KBrvmax in cm
-1): 3352.18 (NH), 2971.66 (C=H), 1810.17
(C=O of amide);1H NMR (DMSO) δ ppm: 3.83 (s, 6H, OCH3), 4.19 (s, 2H, CH2), 6.98-7.61
(m, 3H), 7.69-8.05 (m, 5H), 8.12 (s, 1H, NH), 9.98 (s, 1H, N=CH);13C NMR (DMSO) δ
ppm: 170.09, 169.96, 159.91, 152.10, 149.92, 134.26, 132.10, 130.66, 128.81, 127.99,
127.58, 126.96, 124.69, 111.77, 108.92, 56.11, 39.96; m/z: 382.11 (100.0%), 383.11 (22.9%),
384.11 (5.6%), 384.12 (2.1%); Molecular Formula: C19H18N4O3S; Elemental Analysis:




Yield: 86%; M.P: 138--1400C ; IR (KBrvmax in cm
-1): 3350.18 (NH), 2972.66 (C=H),
1810.17 (C=O of amide);1H NMR (DMSO) δ ppm: 3.85 (s, 9H, OCH3), 4.19 (s, 2H,
CH2), 6.98-7.61 (m, 3H), 7.69-8.05 (m, 5H), 8.12 (s, 1H, NH), 9.98 (s, 1H, N=CH);
13C
NMR (DMSO) δ ppm: 170.09, 169.96, 159.91, 152.10, 149.92, 134.26, 132.10, 130.66,
128.81, 127.99, 127.58, 126.96, 124.69, 111.77, 108.92, 56.11, 39.96; m/z: 412.12
(100.0%), 413.12 (24.1%), 414.12 (5.9%), 414.13 (2.3%), 415.12 (1.1%); Molecular
Formula: C20H20N4O4S; Elemental Analysis: Calculated: (C, H, N, O, S) 58.24, 4.89,




Yield: 88%; M.P: 134-1380C ; IR (KBrvmax in cm
-1): 3350.18 (NH), 2972.66 (C=H),
1810.17 (C=O of amide);1H NMR (DMSO) δ ppm: 3.86 (s, 9H, OCH3), 4.20 (s, 2H,
CH2), 6.99-7.65 (m, 3H), 7.67-8.07 (m, 5H), 8.17 (s, 1H, NH), 9.99 (s, 1H, N=CH);
13C
NMR (DMSO) δ ppm: 171.09, 168.96, 158.91, 153.10, 148.92, 135.26, 133.10, 131.66,
129.81, 128.99, 127.58, 126.96, 125.19, 110.97, 109.12, 55.35, 37.96; m/z: 412.12
(100.0%), 413.12 (24.1%), 414.12 (5.9%), 414.13 (2.3%), 415.12 (1.1%); Molecular
Formula: C20H20N4O4S; Elemental Analysis: Calculated: (C, H, N, O, S) 58.24, 4.89,
13.58, 15.52, 7.77, Found: 58.23, 4.85, 13.55, 15.54, 7.78.
(E)-N-((5-(furan-2-ylmethyleneamino)-1,3,4-thiadiazol-2-yl)methyl)benzamide (7k)
Yield: 85%; M.P: 124-1260C ; IR (KBrvmax in cm
-1): 3350.41 (NH), 2970.76 (C=H),
1810.26 (C=O of amide);1H NMR (DMSO) δ ppm: 3.48 (s, 2H, CH2), 6.52 (t, 1H), 6.93
(d, 1H), 7.65 (d, 1H), 7.80 (s, 1H, N=CH), 7.75-8.05 (m, 5H), 8.19 (s, 1H, NH);13C
NMR (DMSO) δ ppm: 168.09, 167.34, 150.44, 146.99, 144.48, 134.29, 131.11, 128.57,
128.04, 127.54, 126.99, 118.90, 112.26, 40.12; m/z: 312.07 (100.0%), 313.07 (18.7%),
314.06 (4.5%), 314.07 (2.0%); Molecular Formula: C15H12N4O2S; Elemental Analysis:





Yield: 84%; M.P: 136-1380C; IR (KBrvmax in cm
-1): 3350.18 (NH), 2975.66 (C=H),
1815.17 (C=O of amide);1H NMR (DMSO) δ ppm: 4.46 (s, 2H, CH2), 7.17 (t, 1H, CH),
7.63-8.09 (m, 6H), 8.29 (s, 1H, NH);13C NMR (DMSO) δ ppm: 39.91, 127.00, 127.44,
127.99, 128.34, 128.89, 130.73, 132.77, 134.55, 142.98, 152.69, 167.98; m/z: 328.05
(100.0%), 329.05 (16.4%), 330.04 (9.1%), 329.04 (3.1%), 330.05 (2.0%), 331.04 (1.7%);
Molecular Formula: C15H12N4O2S2; Elemental Analysis: Calculated: (C, H, N, O, S)
54.86, 3.68, 17.06, 4.87, 19.53, Found: 54.84, 3.64, 17.03, 4.88, 19.55.
Biological Evaluation:  
In-Vitro Anticancer Evaluation
 The anticancer evaluation of synthesized compounds o  selected cell lines 
i. e. HL-60, HeLa, MCF-7 and SK-MEL-2 was conducted at ACTREC 
(Advanced Centre for Treatment Research and Education in Cancer), 
Mumbai.
 MTT assay of the compounds 7(a-l) was performed using Adriamycin as 
the standard drug. The experiments were performed at the concentration of 
10, 20, 40 and 80 µg/ml.
 The inhibition of cell growth was calculated in terms of:




MCF-7 HeLa SK-MEL-2 HL-60
7a 22.9 32.8 21.9 21.7
7b 28.7 39.0 22.9 28.2
7c 32.4 41.1 27.5 33.3
7d 36.7 52.4 34.0 40.2
Table 2 In-vitro anticancer activity of synthesized compounds 7 (a-l).
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7e 35.2 46.8 28.1 39.6
7f 38.4 49.2 30.0 37.5
7g 41.0 66.1 46.4 42.4
7h 46.2 71.7 49.1 48.2
7i 49.0 78.0 52.6 45.8
7j 51.4 78.8 55.7 49.9
7k 11.7 23.8 19.6 35.5
7l 19.0 28.8 22.0 29.9
ADR <10 <10 <10 <10
In Silico ADMET Prediction
A computational study of synthesized compounds7(a–l) was performed for
prediction of ADMET. The absorption, distribution, metabolism, excretion and
Toxicity (ADMET) properties of all compounds were predicted using Qikprop
v3.5 (Schrödinger LLC). In the present study, we have calculted the molecular
weight (MW), Predictedoctanol-waterpartitioncoefficient(log Po/w),number
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of hydrogen bond acceptors (n-ON), number of hydrogen bondsdonors (n-
OHNH), Percentage human oral absorption (% ABS), Polar surface area (PSA),
Aqueous solubility (Log S), Prediction of binding to human serum albumin
(Log Khsa) andin silico cardiac toxicity study (Log HERG). The above
described properties help us in understanding the ADMET properties of any
drug/synthesized molecule. A molecule likely to be developd as an orally
active drug candidate should show no more than one violationof Lipinski rule
of 5
Table 3 In silico physicochemical pharmacokinetic parameters important for go d oral

































7a 356.8 4.82 5.5 1 76.2 0.31 -5.8 98 2 -6.8 0
7b 391.2 5.34 5.5 1 74.4 0.37 -6.1 99 2 -6.6 0
7c 338.3 5.18 6.2 2 98.4 0.02 -4.7 89 3 -6.7 0
24
7d 338.3 5.17 6 2 98.2 0.03 -4.3 88 3 -6.5 0
7e 368.4 5.27 7.2 1 133.3 -0.04 -4.7 75 3 -6.6 0
7f 382.4 5.09 7 2 105.7 0.16 -5.5 91 4 -6.9 0
7g 352.4 4.91 6.2 1 83.9 0.16 -5.1 100 3 -6.7 0
7h 382.4 5.20 7 1 89.0 0.19 -5.4 100 4 -6.7 0
7i 412.2 4.05 7.7 1 95.4 0.17 -5.4 100 5 -6.5 0
7j 412.2 4.08 7.7 1 97.6 0.19 -5.6 100 5 -6.6 0
7k 312.3 3.91 6 1 84.7 -0.11 -4.0 94 3 -6.3 0
7l 328.4 4.11 5 1 85.6 -0.21 -4.2 95 3 -6.2 0
RESULTS AND DISCUSSION
Chemistry
Herein we report the synthesis of novel N-((5-(substituted Methylene Amino)- 1,3,4-
thiadiazol-2-yl)methyl) Benzamide Derivatives using microwave as shownin scheme1. The
physical characterization data of the synthesized compounds7 (a-l) are as shown in Table 1
All the synthesized compounds were characterized by1H-NMR, 13C-NMR, mass
spectroscopy and IR.
In Vitro Anticancer Activity
The synthesized compounds (7a–l) were evaluated for their anticancer activity against
MCF-7 (Humanbreastcancercell line), HeLa (Humancervicalcancercell line), SKMEL-2
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(Human Melanoma cancer cell line) and HL-60 (Human Leukemia cancer cell line) cancer
cell lines.
The results indicated that the compounds,7k, 7l, 7aand7b exhibited significant cancer
cell growth inhibition compared to reference standard Adriamycin againstMCF-7, HeLa,
SKMEL-2 and HL-60 cancer cell lines. From the anticancer activity results, it was observed
that compound7k, which has furan ring was found to have the highest GI50 values of
11.7µg/ml, 23.8µg/ml, 19.6µg/ml and 35.5µg/ml for MCF-7, HeLa, SKMEL-2 and HL-60
cancer cell lines respectively. Compound7l which has thiophene ring was found to have the
good GI50 values of 19.0µg/ml, 28.8µg/ml, 22.0µg/ml and 29.9µg/ml for MCF-7, HeLa,
SKMEL-2 and HL-60 cancer cell lines respectively.
Structural Activity Relationship
Electron withdrawing groups such as chloro (7a, 7b) exhibited
good activity compared to electron donating, polar groups.
Replacement of the phenyl group in the parent compound by furan
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ring in 7k and thiophene ring in7l has shown significant increase in
anticancer activity in comparison to the standard drug Adriamycin.
Compounds containing electron donating, polar groups such as7c,
7d, 7e, 7f, 7g, 7h, 7iand7j are less active in comparison to electron
withdrawing groups such as7aand7b.
In Silico ADMET Prediction
 The prediction of the ADMET parameters prior to the experimental studies is
one of the most important aspects of drug discovery and development of the drug
molecule.
The synthesized compounds exhibited a good % absorption (% ABS) ranging
from 75% to 100%
All the synthesizedcompoundshaveshownaqueoussolubility valueswithin
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the range -6.1 to -4.2.
The compounds showed Log Khsa value ranges between -0.2 to 0.19 this is an
indication that a significant proportion of the compounds are likely to circulate
freely in the blood stream and hence reach the drug target sites.
The HERG K+ channel blockers are potentially toxic and the predicted IC50
values often provide reasonable predictions for cardiac toxici y of drugs in the
early stages of drug discovery . None of the synthesized compounds7 (a-l) are
toxic in nature as shown in Table 3
CONCLUSION
 Total 12 final compounds were synthesized  under mic owave  irradiation as 
per the scheme reported. 
Structures of synthesized compounds were confirmed by spectral study such as 
IR, 1HNMR, 13C NMR and Mass. 
The synthesized compounds were evaluated for anticancer activity on SK-MEL-
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2, MCF-7, HeLa and HL-60 human cancer cell lines by MTT assay.
It appears that, the hybrid molecule (E)-N-((5-(substituted methyleneamino)-
1,3,4-thiadiazol-2-yl)methyl)benzamide derivatives possess very good potential 
for development as novel anticancer agents and can prove a benchmark for the 
development of potential anticancer agents.
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